Brief: Coya Announces Oral Presentation on Regulatory T Cell Expansion Strategy To Target Inflammation In Alzheimer’S Disease
27/10/2023 14:13
Oct 27 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA ANNOUNCES ACCEPTANCE OF ORAL PRESENTATION,
“REGULATORY T
CELL EXPANSION STRATEGY TO TARGET INFLAMMATION IN ALZHEIMER’S
DISEASE: A PHASE 1 FEASIBILITY STUDY,” AT THE 18TH INTERNATIONAL
CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASE IN LISBON
* COYA THERAPEUTICS INC - WILL RELEASE TOP LINE DATA IN
FIRST HALF
OF 2024
Source text for Eikon: ID:nBw5WqJ7La
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)